<!DOCTYPE html>
<html lang="en">
  <head>
    <!-- Required meta tags -->
    <meta charset="utf-8" />
    <meta
      name="viewport"
      content="width=device-width, initial-scale=1, shrink-to-fit=no"
    />
    <link rel="icon" href="favicon.ico" />
    <!-- Bootstrap CSS -->
    <link
      rel="stylesheet"
      href="https://stackpath.bootstrapcdn.com/bootstrap/4.5.2/css/bootstrap.min.css"
      integrity="sha384-JcKb8q3iqJ61gNV9KGb8thSsNjpSL0n8PARn9HuZOnIxN0hoP+VmmDGMN5t9UJ0Z"
      crossorigin="anonymous"
    />
    <link rel="stylesheet" href="./style.css" />
    <script src="https://kit.fontawesome.com/5901743741.js"></script>
    <title>NeuroPn</title>
  </head>
  <body>
    <nav class="navbar navbar-expand-lg">
      <button class="brand-button">
        <!-- <a class="navbar-brand" href="index.html">NeuroPn</a> -->
        <a href="index.html"> <img src="./logo.png" /> </a>
      </button>
      <button
        class="navbar-toggler"
        data-toggle="collapse"
        data-target="#navbar-menu"
      >
        <i class="fas fa-bars menu"></i>
      </button>
      <div id="navbar-menu" class="collapse navbar-collapse">
        <ul class="navbar-nav ml-auto">
          <li class="nav-item">
            <a class="nav-link" href="index.html">Home</a>
          </li>
          <li class="nav-item">
            <a class="nav-link" href="team.html">Our Team</a>
          </li>
          <li class="nav-item">
            <a class="nav-link" href="science.html">Our Focus</a>
          </li>
          <li class="nav-item">
            <a class="nav-link" href="approach.html">Our Approach</a>
          </li>
          <li class="nav-item">
            <a class="nav-link" href="contact.html">Contact Us</a>
          </li>
        </ul>
      </div>
    </nav>

    <div class="content">
      <h2 class="heading">OUR TEAM</h2>

      <p>
        Our Management Team is a strong combination of Scientific and Business
        Development experience. NeuroPn’s Scientific Advisory Board includes
        Leading Disease and Regulatory Experts.
      </p>

      <h3 class="team-type">Management Team</h3>
      <div class="member-container">
        <h4 class="team-member">
          Ish Khanna, PhD - Co-founder and Chief Executive Officer
        </h4>
        <p>
          Dr. Khanna has over 30 years of pharmaceutical industry experience
          with proven record of success in advancing drug molecules from
          “concept to clinic and market” He has held Technical and Executive
          Leadership positions in pharmaceutical companies (Pfizer, Pharmacia,
          Searle, Dr. Reddy’s Labs, Kareus Therapeutics). Dr. Khanna is
          experienced in building balanced discovery portfolio comprising of
          First in Class, Best in Class and Drug Repositioning. Dr. Khanna’s
          areas of expertise include medicinal chemistry, PK/PD correlations of
          drug molecules, IP strategies, lead optimization strategies and novel
          therapeutics for pain, inflammation, cardiovascular and metabolic
          diseases. He is a co-inventor and co-author of over 100 patents and
          peer reviewed science publications. Dr. Khanna is co-inventor of
          celecoxib and multiple clinical agents across therapeutics.
        </p>
      </div>
      <div class="member-container">
        <h4 class="team-member">Sivaram Pillarisetti, PhD - Co-founder</h4>
        <p>
          Dr. Pillarisetti has over 23 years of experience in research in
          Academia and Industry. Most recently he was head of research at Kareus
          Therapeutics and prior to that he was the Vice President of Research
          at Reddy US Therapeutics and Dr Reddy’s Laboratories (DRL). At DRL he
          headed the biology department and was managing activities from
          discovery to clinic. He has successfully brought several drug
          molecules from concept to clinic. Key accomplishments include three
          candidates in Phase 1/2 and several in preclinical development. He has
          been conducting research in the cardiovascular and metabolic diseases
          for over 18 years. Prior to Reddy US Therapeutics/Dr Reddy
          Laboratories, Dr. Pillarisetti had held faculty appointments at
          Columbia University and the North Shore-Long Island Jewish Health
          System in New York, where he established a peptide discovery program
          for Angion Biotech. His areas of expertise include Inflammation, Pain
          and Metabolic diseases. He is the author of over 50 research papers
          and review articles and inventor on several issued patents. Dr.
          Pillarisetti had been an investigator of the American Heart
          association (1996-99) and is a current member of the American Diabetes
          association and a fellow of the American Heart Association.
        </p>
      </div>
      <div class="member-container">
        <h4 class="team-member">Marcus Malkmus, Chief Operative Officer</h4>
        <p>
          Marcus has over 20 years’ experience investing in biotech companies
          and helping them develop successful commercial and business
          development strategies. Marcus is also a Director at Hestia
          Investments focusing on early to mid-stage public and private
          companies in biotechnology and renewable energy. Marcus’ expertise
          includes help build platform opportunities and the strategic
          partnerships to accomplish corporate goals . Marcus is a
          neuroscientist with strong knowledge of unmet needs in
          neurodegenerative diseases. Marcus holds a MS in neuroscience from
          University College London and was a visiting researcher in Physiology
          at the University of Oxford.
        </p>
      </div>
      <div class="member-container">
        <h4 class="team-member">Dominic Schiller, Intellectual Property</h4>
        <p>
          Dominic is a chartered patent attorney with an extensive knowledge of
          the life sciences, healthcare, pharmaceutical, and botanical
          industries. He is entrepreneurial and is a co-founder and director of
          Alterola Biotech Inc, a listed US cannabinoid pharma company, and
          previously co-founded a gene medicine company, Sutura Therapeutics
          Ltd. He is a qualified and practicing European patent attorney with
          over 35-years in the profession.
        </p>
      </div>

      <h3 class="team-type">Scientific Advisors</h3>
      <div class="member-container">
        <h4 class="team-member">Prof. Solomon Tesfaye, MB ChB, MD, FRCP</h4>
        <p>
          Dr. Tesfaye is a Consultant Physician/Endocrinologist, and Honorary
          Professor of Diabetic Medicine at Sheffield Teaching Hospitals and the
          University of Sheffield. Dr. Tesfaye’s research projects include the
          epidemiology, risk factors, pathogenesis, central nervous system
          involvement and treatment of diabetic neuropathy and neuropathic pain.
          Dr. Tesfaye has published a book, over 200 original articles and
          reviews in diabetic neuropathy including a landmark study in the NEJM.
          Prof. Tesfaye was awarded the Prestigious Camillo Golgi Prize of the
          European Diabetes Association in 2014 for major scientific
          contributions in Diabetic Neuropathy. He also received the Arnold
          Bloom Award of Diabetes UK in 2017 for innovative and patient-centered
          diabetes care. Prof. Tesfaye served as Chair the International Expert
          Group on Diabetic Neuropathy 2010/11; and of NEURODIAB (2006-9), the
          largest diabetic neuropathy scientific group in the world.
        </p>
      </div>
      <div class="member-container">
        <h4 class="team-member">Prof. Kelvin Chou, MD</h4>
        <p>
          Dr. Chou is a Clinical Professor in the Departments of Neurology and
          Neurosurgery at Michigan Medicine and was the inaugural Thomas H. and
          Susan C. Brown Early Career Professor in Neurology. Dr. Chou serves as
          Co-Director of the STIM (Surgical Therapies Improving Movement)
          Program with research focus on improving movement disorders through
          deep brain stimulation. Dr. Chou is also an experienced clinical
          trialist, conducting numerous clinical trials on new therapies for
          Parkinson’s disease, essential tremor and Huntington disease. He
          directs the Neurology Clinical Trials Organization (NeCTO) and is Lead
          Medical Director of the Neuroscience and Sensory Clinical Trials
          Support Unit (CTSU) at Michigan Medicine. He has published over 100
          peer-reviewed journal articles, review articles or book chapters on PD
          and related movement disorders.
        </p>
      </div>
      <div class="member-container">
        <h4 class="team-member">Prof. Nanna Finnerup, MD, PhD</h4>
        <p>
          Dr. Finnerup is a Professor in pain research at Danish Pain Research
          Center, Department of Clinical Medicine, Aarhus University. Her areas
          of interest include studying the pathophysiology and therapies for
          diabetic polyneuropathy, chemotherapy-induced neuropathic pain, and
          related neuropathic conditions. Prof Nanna has been involved in
          multiple clinical trials in neuropathic pain and have authored more
          than 150 publications in the field. Currently, Prof. Nanna is Chair of
          the Neuropathic Pain Special Interest Group (NeuPSIG) of the
          International Association for the Study of Pain (IASP) and a steering
          group member of the International Diabetic Neuropathy Center (IDNC).
        </p>
      </div>
      <div class="member-container">
        <h4 class="team-member">Prof. Hideho Okada, MD, PhD</h4>
        <p>
          Dr. Okada is a Professor, Neurological Surgery in the School of
          Medicine at the University of California, San Francisco. Dr. Okada’s
          is a creative physician-scientist and conducted one of the first
          immune gene therapy trials in patients with malignant glioma. Dr.
          Okada served as a Co-Leader of the Brain Tumor Program within the
          University of Pittsburgh Cancer Institute and has worked to expand the
          program by developing strong interdisciplinary and translational
          research activities among program members. In 2010, Dr. Okada was
          selected to be a member of the American Society for Clinical
          Investigation.
        </p>
      </div>
      <div class="member-container">
        <h4 class="team-member">Bob Ings, PhD</h4>
        <p>
          Dr. Ings is a DMPK expert with 40 years experience including senior
          leadership positions (Roche, Daiichi, Amgen, Pharmacia, Servier). Dr.
          Ings contributed to multiple US and European successful registrations
          of new medicines whilst working in the Pharma industry. He has
          co-authered over 80 publications including several book chapters.
        </p>
      </div>
      <div class="member-container">
        <h4 class="team-member">David Hill, PhD</h4>
        <p>
          Dr. Hill has over 30 years of experience working in the pharmaceutical
          industry as a pharmacologist and a senior leader, starting and
          finishing his career with Merck. David’s areas of expertise include:
          drug-discovery for neuroscience, pain, and anesthesia, including the
          use of large and small animal experimental models, and utilization of
          the translational in-vivo and in-vitro technologies for a successful
          path from early discovery to the clinic. During last several years
          David has been involved in novel drug discovery programs to build
          strategies and objective measures to mitigate risk of clinical
          failure.
        </p>
      </div>
      <div class="member-container">
        <h4 class="team-member">Leonid Shapiro, MD, PhD</h4>
        <p>
          Leonid is a medical doctor, entrepreneur and management consultant and
          oversees Candesic&#39;s corporate and commercial due diligence work.
          He consults Private Equity firms, Corporate Operators, and Government
          Organisations in the areas of healthcare, technology, and
          communications focusing on strategy, marketing, and organization.
          Prior to founding Candesic, Leonid was a senior consultant at McKinsey
          &amp; Company, London, working heavily in healthcare and technology.
          He has also consulted to Hewlett-Packard in medical imaging product
          development. Leonid’s entrepreneurial ventures include being COO of a
          $126 M software company and CEO of a telecommunications firm. He holds
          a D.Phil. from Magdalen College, Oxford in Radiological Imaging, a MD
          from Duke University in North Carolina, an undergraduate degree in
          Physics from Cornell University and is fluent in Russian and English.
        </p>
      </div>
    </div>

    <footer>
      <h5 class="footer-title">NeuroPn</h5>
      <div class="footer-content">
        <p class="footer-address">
          <span>4989 Peachtree Parkway</span>
          <span>Suite 200</span>
          <span>Peachtree Corners</span>
          <span>GA 30092 USA</span>
        </p>
        <p class="footer-contact">
          <span>404-939-5786</span>
          <span>business@neuropn.com</span>
        </p>
      </div>
    </footer>

    <!-- Optional JavaScript -->
    <!-- jQuery first, then Popper.js, then Bootstrap JS -->
    <script
      src="https://code.jquery.com/jquery-3.5.1.slim.min.js"
      integrity="sha384-DfXdz2htPH0lsSSs5nCTpuj/zy4C+OGpamoFVy38MVBnE+IbbVYUew+OrCXaRkfj"
      crossorigin="anonymous"
    ></script>
    <script
      src="https://cdn.jsdelivr.net/npm/popper.js@1.16.1/dist/umd/popper.min.js"
      integrity="sha384-9/reFTGAW83EW2RDu2S0VKaIzap3H66lZH81PoYlFhbGU+6BZp6G7niu735Sk7lN"
      crossorigin="anonymous"
    ></script>
    <script
      src="https://stackpath.bootstrapcdn.com/bootstrap/4.5.2/js/bootstrap.min.js"
      integrity="sha384-B4gt1jrGC7Jh4AgTPSdUtOBvfO8shuf57BaghqFfPlYxofvL8/KUEfYiJOMMV+rV"
      crossorigin="anonymous"
    ></script>
  </body>
</html>
